News
MNPR
60.99
-0.73%
-0.45
Monopar Therapeutics GAAP EPS of -$0.46 beats by $0.36
Seeking Alpha · 5h ago
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR)
TipRanks · 13h ago
MONOPAR THERAPEUTICS INC - ON TRACK TO SUBMIT NDA TO FDA IN MID-2026
Reuters · 16h ago
*Monopar Therapeutics 1Q Loss/Shr 46c >MNPR
Dow Jones · 16h ago
Press Release: Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Dow Jones · 16h ago
Weekly Report: what happened at MNPR last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at MNPR last week (0427-0501)?
Weekly Report · 05/04 10:32
Weekly Report: what happened at MNPR last week (0420-0424)?
Weekly Report · 04/27 10:36
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON)
TipRanks · 04/21 13:40
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopar Therapeutics Inc (MNPR)
TipRanks · 04/21 11:00
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Agios Pharma (AGIO)
TipRanks · 04/20 12:50
Monopar Highlights Strong Phase 3 Data for ALXN1840
TipRanks · 04/20 10:48
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification
TipRanks · 04/20 10:45
Weekly Report: what happened at MNPR last week (0413-0417)?
Weekly Report · 04/20 10:31
Monopar says Phase 3 trial shows ALXN1840 beats standard care on neurologic Wilson disease outcomes
PUBT · 04/20 10:22
Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840
TipRanks · 04/20 00:50
Monopar says Phase 3 trial shows ALXN1840 beats standard care in neurologic Wilson disease
PUBT · 04/19 23:00
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Barchart · 04/19 18:00
Weekly Report: what happened at MNPR last week (0406-0410)?
Weekly Report · 04/13 10:36
Monopar Therapeutics Inc (MNPR) Gets a Buy from JonesTrading
TipRanks · 04/06 20:37
More
Webull provides a variety of real-time MNPR stock news. You can receive the latest news about Monopar Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.